Also, the effects of HPT-treatment on FGF23 and phosphate homeostasis should be taken into account: RCTs with dialysis patients have shown that strict phosphate control significantly delays progression of coronary artery calcification [78] and that FGF23 suppression with the calcimimetic etelcalcetide inhibits left ventricular hypertrophy [79]. Here, FGF23 is linked to coronary artery calcification.